Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 282 Shares

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 282 shares of the company's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $44.90, for a total value of $12,661.80. Following the sale, the senior vice president now owns 133,433 shares of the company's stock, valued at approximately $5,991,141.70. The trade was a 0.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Paula Green also recently made the following trade(s):

• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total transaction of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $64,656.00.
• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10.

Twist Bioscience Stock Up 0.7 %

TWST stock traded up $0.32 during trading on Thursday, reaching $49.22. The stock had a trading volume of 486,879 shares, compared to its average volume of 940,682. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company's 50 day moving average is $45.51 and its two-hundred day moving average is $46.72. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -13.67 and a beta of 1.82.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB purchased a new position in Twist Bioscience in the third quarter valued at about $34,000. Signaturefd LLC boosted its holdings in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after acquiring an additional 306 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in shares of Twist Bioscience in the second quarter valued at $61,000. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at $95,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TWST shares. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective on the stock. Scotiabank upped their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research note on Tuesday, November 19th. Evercore ISI increased their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. Leerink Partners upped their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Finally, TD Cowen reaffirmed a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.